Characteristics of relapsed acute promyelocytic leukemia patients
| Patient no. . | Risk category . | Age (y) . | Sex . | Cytogenetics . | FLT3 status . | Time to first relapse (mo) . | Type of first relapse . |
|---|---|---|---|---|---|---|---|
| 1 | High | 52 | F | Diploid | ND | 9.2 | Molecular* |
| 2 | Low | 42 | M | 46XY t(15;17) [20] | ND | 79.5 | Hematological/molecular |
| 3 | High | 38 | M | 46XY t(15;17) [19] | ND | 9 | Hematological/molecular |
| 4 | High | 79 | M | 46XY t(15;17), der (17) i (17) (q10) [18]; 46 XY [2] | Neg | 12.4 | Molecular* |
| 5 | High | 18 | M | 46XY t(15;17) [19] | ND | 9.4 | Molecular* |
| 6 | Low | 19 | F | Diploid | Neg | 9.5 | Hematological |
| 7 | High | 35 | M | 46XY t(15;17) [16]; 46 idem, del 7 [1]; 46 XY [3] | Neg | 7.9 | Hematological |
| Patient no. . | Risk category . | Age (y) . | Sex . | Cytogenetics . | FLT3 status . | Time to first relapse (mo) . | Type of first relapse . |
|---|---|---|---|---|---|---|---|
| 1 | High | 52 | F | Diploid | ND | 9.2 | Molecular* |
| 2 | Low | 42 | M | 46XY t(15;17) [20] | ND | 79.5 | Hematological/molecular |
| 3 | High | 38 | M | 46XY t(15;17) [19] | ND | 9 | Hematological/molecular |
| 4 | High | 79 | M | 46XY t(15;17), der (17) i (17) (q10) [18]; 46 XY [2] | Neg | 12.4 | Molecular* |
| 5 | High | 18 | M | 46XY t(15;17) [19] | ND | 9.4 | Molecular* |
| 6 | Low | 19 | F | Diploid | Neg | 9.5 | Hematological |
| 7 | High | 35 | M | 46XY t(15;17) [16]; 46 idem, del 7 [1]; 46 XY [3] | Neg | 7.9 | Hematological |
BM, bone marrow; CNS, central nervous system; F, female; M, Male; MRD-SCT, matched-related donor stem cell transplantation; mo, months; No., number; ND, not done; Neg, negative.
Molecular relapses: Patient No.1 experienced a molecular relapse after 9.2 mo received salvage ATRA/ATO/GO achieved molecular remission, but then had a hematological relapse (BM+CNS) with time to hematological relapse of 18.8 mo (9.6 mo after molecular relapse). Patient No. 4 experienced a molecular relapse after 12.4 mo received salvage GO without achieving molecular remission and had a hematological relapse (CNS alone) with time to hematological relapse of 16.4 mo (4 mo after molecular relapse). Patient No. 5 experienced a molecular relapse after 9.4 mo received salvage ATRA/ATO/GO/IDA achieved molecular remission which was followed by MRD-SCT.